Meeting
2016 Gastrointestinal Cancers Symposium
Synergy of water soluble prodrug triptolide (minnelide) with gemcitabine and nab-paclitaxel in pancreatic cancer.
Authors
Vikas Dudeja
Department of Surgery, University of Minnesota, Minneapolis, MN
Vikas Dudeja , Shrey Modi , Bhuwan Giri , Kaustav Majumder , Sulagna Banerjee , Ashok Saluja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 259)
DOI
10.1200/jco.2016.34.4_suppl.259
Abstract #
259
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
Evaluation of efficacy of oral administration of pro-drug of triptolide against pancreatic cancer.
First Author: Vikas Dudeja
Poster
2022 ASCO Annual Meeting
Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.
First Author: Manish Sharma
Poster
2019 Gastrointestinal Cancers Symposium
Dose intensity of nab-paclitaxel and gemcitabine chemotherapy in metastatic pancreatic cancer.
First Author: Alexander Lim
Poster
2019 Gastrointestinal Cancers Symposium
Real world usage of gemcitabine and nabpaclitaxel in older adults with metastatic pancreatic cancer: A single institution experience.
First Author: Arthur Winer